SenesTech (SNES)
Market Price (9/18/2026): $0.825 | Market Cap: $4.4 MilSector: Materials | Industry: Specialty Chemicals
SenesTech (SNES)
Market Price (9/18/2026): $0.825Market Cap: $4.4 MilSector: MaterialsIndustry: Specialty Chemicals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -57% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -52% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Sustainable Consumption. Themes include Animal Fertility & Population Control, and Eco-friendly Pest Management. | Weak multi-year price returns2Y Excs Rtn is -109%, 3Y Excs Rtn is -170% | Penny stockMkt Price is 0.8 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -304% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 12% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -281%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -284% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -163% Key risksSNES key risks include [1] a persistent failure to achieve profitability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -57% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -52% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Sustainable Consumption. Themes include Animal Fertility & Population Control, and Eco-friendly Pest Management. |
| Weak multi-year price returns2Y Excs Rtn is -109%, 3Y Excs Rtn is -170% |
| Penny stockMkt Price is 0.8 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.2 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -304% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -281%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -284% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -163% |
| Key risksSNES key risks include [1] a persistent failure to achieve profitability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
SenesTech (SNES) stock has lost about 50% since 5/31/2026 because of the following key factors:
1. Continued widening of net losses despite revenue growth. For fiscal Q2 2026, which ended June 30, 2026, SenesTech reported revenue of $0.77 million, exceeding analyst expectations and showing a 23% year-over-year increase and 56% sequential growth from fiscal Q1 2026. The company also achieved a record gross margin of 73.6%. However, operating expenses, particularly selling, general, and administrative (SG&A) expenses, increased by $456,000 to $2.05 million, outpacing gross profit growth. This resulted in a widened operating loss of $1.86 million, a 15% increase year-over-year, and a net loss of $1.83 million, up 13% year-over-year. This indicates that despite top-line improvements, the company struggled with profitability and cost control.
2. Deteriorating financial position and significant cash burn. SenesTech's liquidity saw a notable decline, with cash and cash equivalents decreasing by approximately $3.49 million during the first half of fiscal 2026 (from year-end 2025 to June 30, 2026). The company also reported negative operating cash flow of -$6.68 million and negative free cash flow of -$6.74 million over the last 12 months. Furthermore, as of September 5, 2026, the company's Altman Z-Score, a measure of bankruptcy probability, stood at a concerning -20.76, suggesting an increased risk of bankruptcy.
Show more
SenesTech (SNES) stock has lost about 50% since 5/31/2026 because of the following key factors:
1. Continued widening of net losses despite revenue growth. For fiscal Q2 2026, which ended June 30, 2026, SenesTech reported revenue of $0.77 million, exceeding analyst expectations and showing a 23% year-over-year increase and 56% sequential growth from fiscal Q1 2026. The company also achieved a record gross margin of 73.6%. However, operating expenses, particularly selling, general, and administrative (SG&A) expenses, increased by $456,000 to $2.05 million, outpacing gross profit growth. This resulted in a widened operating loss of $1.86 million, a 15% increase year-over-year, and a net loss of $1.83 million, up 13% year-over-year. This indicates that despite top-line improvements, the company struggled with profitability and cost control.
2. Deteriorating financial position and significant cash burn. SenesTech's liquidity saw a notable decline, with cash and cash equivalents decreasing by approximately $3.49 million during the first half of fiscal 2026 (from year-end 2025 to June 30, 2026). The company also reported negative operating cash flow of -$6.68 million and negative free cash flow of -$6.74 million over the last 12 months. Furthermore, as of September 5, 2026, the company's Altman Z-Score, a measure of bankruptcy probability, stood at a concerning -20.76, suggesting an increased risk of bankruptcy.
3. Negative market reaction to Q2 2026 earnings despite beating estimates. Despite beating consensus estimates for both EPS (reporting -$0.35 vs. -$0.37 expected) and revenue in fiscal Q2 2026, SenesTech's stock experienced a significant decline of 22.09% on August 5, 2026, the day the earnings were reported. This adverse market response suggests that investors were more focused on the company's worsening net loss and overall cash burn rather than the modest beats on analyst expectations.
4. Divergent and largely cautious analyst and valuation outlooks. While some analyst price targets, as of August 2026, implied significant upside (e.g., an average target of $6.75 from two analysts, suggesting 335.48% upside from a price of $1.55), other valuation models presented a more pessimistic view. GuruFocus's proprietary GF Value estimated the stock at $0.41, indicating a potential downside of -73.55% from a price of $1.55 as of August 4, 2026, suggesting the stock was "Significantly Overvalued." Additionally, StockInvest.us rated SenesTech as a "Strong Sell Candidate" with a technical score of -6.23 as of September 4, 2026. These conflicting but often negative outlooks likely contributed to investor uncertainty and selling pressure.
Show less
Stock Movement Drivers
Fundamental Drivers
The -52.0% change in SNES stock from 5/31/2026 to 9/17/2026 was primarily driven by a -54.6% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9172026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.73 | 0.83 | -52.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | 6.5% |
| P/S Multiple | 4.1 | 1.9 | -54.6% |
| Shares Outstanding (Mil) | 5 | 5 | -0.7% |
| Cumulative Contribution | -52.0% |
Market Drivers
5/31/2026 to 9/17/2026| Return | Correlation | |
|---|---|---|
| SNES | -52.0% | |
| Market (SPY) | 0.8% | 26.5% |
| Sector (XLB) | -0.9% | 19.1% |
Fundamental Drivers
The -63.1% change in SNES stock from 2/28/2026 to 9/17/2026 was primarily driven by a -59.4% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9172026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.25 | 0.83 | -63.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | 3.2% |
| P/S Multiple | 4.6 | 1.9 | -59.4% |
| Shares Outstanding (Mil) | 5 | 5 | -12.0% |
| Cumulative Contribution | -63.1% |
Market Drivers
2/28/2026 to 9/17/2026| Return | Correlation | |
|---|---|---|
| SNES | -63.1% | |
| Market (SPY) | 11.5% | 12.6% |
| Sector (XLB) | -4.6% | 5.9% |
Fundamental Drivers
The -83.2% change in SNES stock from 8/31/2025 to 9/17/2026 was primarily driven by a -65.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 9172026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.94 | 0.83 | -83.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | 13.4% |
| P/S Multiple | 4.4 | 1.9 | -57.6% |
| Shares Outstanding (Mil) | 2 | 5 | -65.0% |
| Cumulative Contribution | -83.2% |
Market Drivers
8/31/2025 to 9/17/2026| Return | Correlation | |
|---|---|---|
| SNES | -83.2% | |
| Market (SPY) | 19.2% | 25.1% |
| Sector (XLB) | 11.5% | 12.9% |
Fundamental Drivers
The -98.8% change in SNES stock from 8/31/2023 to 9/17/2026 was primarily driven by a -99.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312023 | 9172026 | Change |
|---|---|---|---|
| Stock Price ($) | 69.36 | 0.83 | -98.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 2 | 118.8% |
| P/S Multiple | 1.5 | 1.9 | 21.7% |
| Shares Outstanding (Mil) | 0 | 5 | -99.6% |
| Cumulative Contribution | -98.8% |
Market Drivers
8/31/2023 to 9/17/2026| Return | Correlation | |
|---|---|---|
| SNES | -98.8% | |
| Market (SPY) | 75.3% | 15.6% |
| Sector (XLB) | 29.1% | 12.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SNES Return | -43% | -84% | -97% | -74% | -35% | -62% | -100% |
| Peers Return | 41% | -42% | -1% | 23% | 15% | -21% | -9% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| SNES Win Rate | 33% | 33% | 17% | 33% | 42% | 22% | |
| Peers Win Rate | 60% | 35% | 46% | 46% | 42% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| SNES Max Drawdown | -59% | -88% | -99% | -86% | -65% | -66% | |
| Peers Max Drawdown | -40% | -61% | -40% | -43% | -50% | -45% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: FUL, GEVO, FSI, LOOP, STDN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/17/2026 (YTD)
How Low Can It Go
| Event | SNES | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -60.2% | -18.8% |
| % Gain to Breakeven | 151.1% | 23.1% |
| Time to Breakeven | 66 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -36.1% | -7.8% |
| % Gain to Breakeven | 56.5% | 8.5% |
| Time to Breakeven | 355 days | 18 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -18.2% | -19.2% |
| % Gain to Breakeven | 22.2% | 23.8% |
| Time to Breakeven | 7 days | 105 days |
In The Past
SenesTech's stock fell -60.2% during the 2025 US Tariff Shock. Such a loss loss requires a 151.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | SNES | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -60.2% | -18.8% |
| % Gain to Breakeven | 151.1% | 23.1% |
| Time to Breakeven | 66 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -36.1% | -7.8% |
| % Gain to Breakeven | 56.5% | 8.5% |
| Time to Breakeven | 355 days | 18 days |
In The Past
SenesTech's stock fell -60.2% during the 2025 US Tariff Shock. Such a loss loss requires a 151.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About SenesTech (SNES)
SenesTech, Inc. is a Phoenix, Arizona-based biotechnology company specializing in innovative pest management solutions. Unlike traditional methods that rely on lethal control, SenesTech focuses on a humane and sustainable approach by developing technologies for animal pest population management through fertility control. The company aims to offer environmentally conscious alternatives to address pervasive pest challenges.
The company's primary product is ContraPest, a proprietary liquid bait specifically designed to limit the reproduction of both male and female rats. By targeting the reproductive capabilities of these pests, ContraPest provides a non-lethal method to reduce and control rat populations, offering a different paradigm compared to conventional rodenticides.
SenesTech's market includes professional pest control operators, municipalities, commercial enterprises, and other organizations that require effective yet environmentally responsible solutions for managing rodent populations. The company serves customers seeking advanced, non-lethal technologies to address rat infestations in urban, agricultural, and commercial settings, emphasizing long-term population reduction over immediate eradication.
```AI Analysis | Feedback
1. Pfizer for rats.
2. Bayer for rat birth control.
AI Analysis | Feedback
- ContraPest: A liquid bait designed to control rat populations by limiting the reproduction of both male and female rats.
AI Analysis | Feedback
SenesTech (SNES) primarily sells to other companies and governmental entities rather than individual consumers. The company's customer base is diffuse, and it does not typically disclose specific major customers (i.e., those accounting for 10% or more of revenue) in its public filings. Therefore, its customers can be best described by category:
-
Professional Pest Control Operators (PCOs): These are companies that purchase ContraPest to use as part of their pest management services offered to their own clients across various sectors (residential, commercial, industrial, agricultural). PCOs represent a significant channel for SenesTech's products.
-
Commercial Businesses: A wide range of businesses that directly manage rat populations on their properties. This includes industries such as food processing facilities, agricultural operations (e.g., farms, feedlots), warehouses, manufacturing plants, public health facilities, and zoological facilities.
-
Government and Municipal Entities: Various governmental bodies, including city and county public health departments, municipalities, and other agencies responsible for managing pest infestations in public spaces, infrastructure, and government-owned properties.
AI Analysis | Feedback
AI Analysis | Feedback
Joel Fruendt, Chief Executive Officer
Joel Fruendt was appointed CEO of SenesTech in November 2022. He is a seasoned chief executive with over 30 years of extensive sales, marketing, and general management leadership. His experience includes 15 years of executive leadership in the vector and pest control industries, where he served as Vice President and General Manager of Clarke Environmental Inc. Mr. Fruendt also brings expertise in the development and manufacturing of EPA-registered chemical control products, commercialization, and leading large sales and service organizations. Most recently, he was President and CEO of a global manufacturing company in the reflective technology and safety industry, where he spearheaded successful revenue and profit growth through innovation and efficiency initiatives. Mr. Fruendt plans to retire by June 30, 2026.
Tom Chesterman, Chief Financial Officer
Tom Chesterman joined SenesTech as CFO in September 2015. He possesses over 20 years of experience as the CFO of public companies across the life science, technology, and telecommunications sectors. Previously, he was the VP and Treasurer of GCI, a telecommunications company in Alaska. His earlier roles include serving as CFO for life science companies such as Bio-Rad Laboratories, Aradigm, and Bionovo. Mr. Chesterman is proficient in various capital market access techniques and has a demonstrated history of developing operational and financial infrastructure to support rapid growth.
Dr. Jamie Bechtel, Interim Executive Chair
Dr. Jamie Bechtel was appointed Interim Executive Chair in January 2026 to support the CEO transition and ensure strategic alignment, execution discipline, and clear communication between the Board and the organization. She also serves as the Chairman of SenesTech's Board of Directors.
Courtney Ray, Vice President, Science & Innovation
Courtney Ray is the Vice President of Science & Innovation at SenesTech. Her background includes work in academia, government, and the nonprofit sector, focusing on research initiatives in wildlife management. She leverages her industry knowledge and cross-disciplinary experience to foster business growth, strengthen partnerships, and advance the adoption of fertility control solutions.
Bryan DiMenna, Vice President, Sales
Bryan DiMenna is the Vice President, Sales at SenesTech Inc. Throughout his career, he has worked with Fortune 500 companies such as BASF and dsm-firmenich, where he successfully led through challenging market conditions to grow both margin and top-line revenue. He is responsible for designing and executing the global commercial strategy for SenesTech's innovative rodent contraceptive products.
AI Analysis | Feedback
The key risks to SenesTech's business are primarily centered around its financial viability, the challenges of market adoption for its innovative products, and the ongoing need for regulatory navigation and successful product execution.
- Financial Distress and Path to Profitability: SenesTech faces significant financial challenges, indicated by an Altman Z-Score suggesting financial distress and a potential risk of bankruptcy. The company has reported substantial net losses, with $6.4 million in 2025 and $6.2 million in 2024, contributing to an accumulated deficit of $142.5 million. Despite revenue growth, its profitability metrics show considerable challenges, including operating and net margins well into negative territory. SenesTech is currently unprofitable and is not projected to reach profitability within the next three years, necessitating additional capital and broader market adoption to achieve a sustainable financial position. This persistent negative cash flow and high cash burn rate represent a significant liquidity risk, potentially leading to continuous shareholder dilution.
- Market Adoption Challenges and Competition: SenesTech's business model relies on a paradigm shift in pest management—fertility control—which requires extensive and costly long-term educational efforts to change entrenched customer behavior among pest management professionals and consumers. The company faces limited market awareness and slower adoption compared to traditional rodenticides. While SenesTech currently holds a first-mover advantage with the only EPA-registered rodent contraceptives, this is considered a temporary competitive moat. There is a risk that larger, better-funded competitors, such as major agricultural or chemical companies, could dedicate significant research and development resources to develop similar competing products, challenging SenesTech's market position.
- Regulatory Hurdles and Product Dependence: As a biotech company, SenesTech is subject to inherent challenges, including regulatory hurdles and the continuous need for innovation within the industry. Gaining regulatory approvals for its products, particularly in international markets, can be time-consuming and introduces uncertainty regarding shipment schedules and overall market entry. Furthermore, the company has strategically shifted its focus, increasing its reliance on the successful execution and growth of its Evolve product line. Any significant issues with the Evolve product could have a magnified impact on the business.
AI Analysis | Feedback
AI Analysis | Feedback
SenesTech's main products, ContraPest and Evolve (which includes Evolve Rat and Evolve Mouse), address significant markets within rodent control through fertility management.
- The product market for controlling rat and mouse populations in the U.S. is approximately $1 billion.
- Internationally, the market for controlling rat and mouse populations is over $4.5 billion.
- SenesTech also identifies an addressable market size of close to $200 million specifically for their Elevate System, which targets roof rats in the poultry market.
- The introduction of the Evolve Mouse product in May 2024 further expanded the company's addressable market by targeting mice.
More broadly, the global rodent control market was valued at approximately $2.95 billion in 2024 and is projected to reach $4.739 billion by 2031. Another estimate places the global market at $3.22 billion in 2024, with projections to reach $5.53 billion by 2033. The North American rodent control market alone held a significant share, with a market size of approximately $1.18 billion in 2024.
AI Analysis | Feedback
SenesTech, Inc. (NASDAQ: SNES) is poised for future revenue growth over the next 2-3 years, driven by several strategic initiatives and market expansions. These key drivers include the continued rollout and adoption of its new Evolve product line, expansion within e-commerce channels, penetration into municipal and agricultural markets, and a focused international growth strategy.
Here are 3-5 expected drivers of future revenue growth for SenesTech:
-
Growth of the Evolve Soft Bait Product Line: The Evolve soft bait fertility control product, launched in late 2023 and early 2024, is identified as a "game-changing product" and a primary driver for future sales growth. It offers similar efficacy to the company's flagship ContraPest but with an improved form factor, a more economical price point, and an extended shelf life, facilitating broader distribution to new retail customers and end markets. The success of Evolve has already led SenesTech to expand its manufacturing capabilities. In Q4 2024, Evolve Rat and Evolve Mouse collectively constituted a significant majority of the company's sales.
-
Expansion and Direct Management of E-commerce Channels: E-commerce has emerged as a crucial revenue stream for SenesTech, accounting for over 50% of its total revenue in 2025. A strategic shift implemented in February 2026 involves directly managing the sales of Evolve Rat and Evolve Mouse products on Amazon, moving away from third-party management. This transition is anticipated to boost revenue and enhance profit margins by providing SenesTech with greater control over product presentation, optimizing sales and marketing efforts, and allowing the company to retain a larger portion of e-commerce revenue. E-commerce sales of Evolve have consistently demonstrated steady growth.
-
Penetration into Municipal and Agricultural Markets: SenesTech is actively expanding its presence in municipal and agricultural sectors, which are expected to be significant growth catalysts. Municipal sales notably increased by 139% year-over-year in Q3 2025, driven by expanded deployments in major urban centers such as New York City, Chicago, and Baltimore. The company foresees substantial growth opportunities from ongoing trials and potential partnerships within these sectors.
-
International Expansion: International market expansion represents another vital driver for revenue growth. SenesTech's plans for international growth are spearheaded by its efforts in New Zealand, where Evolve received approval in February 2026. The company is also pursuing potential approval in Australia. Further expanding its global footprint, SenesTech appointed the Belize Raptor Center as an official distributor for Evolve Rat Birth Control in November 2025.
-
Broadened Retail Rollout and Partnerships: SenesTech is pursuing a strategy of gradual retail rollout and establishing new partnerships. Retail sales experienced a substantial 254% year-over-year increase in Q3 2025. This growth was fueled by expanded adoption with existing partners like Ace Hardware and follow-on orders from a wholesaler serving over 8,000 retail locations. Furthermore, SenesTech's products are now available through Lowe's.com, indicating an expanding retail presence.
AI Analysis | Feedback
Share Issuance
- SenesTech strengthened its balance sheet through capital raises in 2025, resulting in $8.6 million in cash and short-term investments at year-end.
- Through December 31, 2025, the company had received net proceeds of $107.7 million primarily from the sales of equity securities, including warrant exercises.
- In the first quarter of 2025, SenesTech raised over $1 million from an at-the-market (ATM) facility and approximately $1 million from warrant exercises.
Inbound Investments
- Capital raises completed in 2025 provided $8.6 million in cash and short-term investments, effectively representing inbound investments from equity and warrant exercises.
- The company relies on the sale of equity securities as a primary means of financing its operations.
- As of March 4, 2026, institutional investors held 796,823 shares of SenesTech, indicating ongoing inbound investment interest.
Capital Expenditures
- In the last 12 months (presumably ending late 2025), SenesTech reported capital expenditures of -$140,000.
- Investment in product development is a focus area, entailing substantial upfront capital expenditures.
Peer Outperformance in Specialty Chemicals
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Copper | 7 | 76.6% | 78.9% | 313.2% | COPR 1000% · HBM 369% · TGB 348% |
| Steel | 13 | 16.9% | 41.4% | 172.3% | HCC 335% · STLD 327% · NWPX 312% |
| Silver | 6 | 115.3% | 318.6% | 166.4% | AYA 312% · HL 247% · SVM 201% |
| Gold | 34 | 27.5% | 200.3% | 156.7% | IAG 765% · KGC 467% · CNL 436% |
| Aluminum | 3 | 54.4% | 127.8% | 66.1% | CENX 213% · KALU 66% · AA 1% |
| Construction Materials | 7 | -21.6% | 17.8% | 48.9% | USLM 366% · CRH 82% · VMC 50% |
| Diversified Metals & Mining | 23 | -17.7% | -7.1% | 11.0% | ATLX 204186% · USAR 52350% · TII 722% |
| Metal, Glass & Plastic Containers | 10 | -5.4% | 13.4% | 7.5% | KRT 218% · MYE 84% · GEF 58% |
| Paper & Plastic Packaging Products & Materials | 7 | 7.6% | 7.6% | -8.2% | PKG 94% · CCK 10% · SON -2% |
| Specialty Chemicals ← | 41 | 8.0% | -3.1% | -10.1% | ODC 465% · NEU 204% · CMT 93% |
| Commodity Chemicals | 11 | 20.6% | 12.6% | -18.1% | HWKN 275% · KOP 63% · LXU 54% |
| Diversified Chemicals | 4 | -5.4% | -29.1% | -28.6% | CBT 73% · ASH -15% · CC -43% |
| Precious Metals & Minerals | 8 | 37.6% | 167.7% | -33.7% | ASM 631% · PPTA 385% · MTA 39% |
| Fertilizers & Agricultural Chemicals | 10 | -11.8% | -6.6% | -34.1% | CF 203% · CTVA 106% · NTR 49% |
| Paper Products | 3 | -20.0% | -50.7% | -96.0% | CLW -37% · ITP -96% · MERC -96% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| SenesTech Earnings Notes | 12/16/2025 | |
| Would You Still Hold SenesTech Stock If It Fell Another 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 3.73 |
| Mkt Cap | 0.1 |
| Rev LTM | 21 |
| Op Inc LTM | -8 |
| FCF LTM | -8 |
| FCF 3Y Avg | -7 |
| CFO LTM | -7 |
| CFO 3Y Avg | -6 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -2.6% |
| Rev Chg 3Y Avg | 30.4% |
| Rev Chg Q | -2.3% |
| QoQ Delta Rev Chg LTM | -0.5% |
| Op Inc Chg LTM | -18.5% |
| Op Inc Chg 3Y Avg | 3.2% |
| Op Mgn LTM | -127.3% |
| Op Mgn 3Y Avg | -185.9% |
| QoQ Delta Op Mgn LTM | -0.9% |
| CFO/Rev LTM | -114.0% |
| CFO/Rev 3Y Avg | -142.7% |
| FCF/Rev LTM | -157.8% |
| FCF/Rev 3Y Avg | -252.4% |
Price Behavior
| Market Price | $0.83 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 12/08/2016 | |
| Distance from 52W High | -82.9% | |
| 50 Days | 200 Days | |
| DMA Price | $1.22 | $1.75 |
| DMA Trend | down | down |
| Distance from DMA | -32.2% | -52.7% |
| 3M | 1YR | |
| Volatility | 75.6% | 84.0% |
| Downside Capture | 417.79 | 354.98 |
| Upside Capture | 9.57 | 93.98 |
| Correlation (SPY) | 25.2% | 25.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 4.29 | 2.73 | 1.60 | 0.83 | 1.66 | 1.32 |
| Up Beta | 8.04 | 6.30 | 2.53 | 1.65 | 1.72 | 1.45 |
| Down Beta | -14.85 | -3.20 | 0.45 | -0.56 | 0.44 | 1.02 |
| Up Capture | 184% | 133% | 54% | 7% | 87% | 8% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 6 | 19 | 25 | 48 | 92 | 324 |
| Down Capture | 820% | 409% | 255% | 178% | 183% | 112% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 13 | 21 | 34 | 70 | 147 | 402 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SNES | |
|---|---|---|---|---|
| SNES | -82.5% | 83.9% | -1.71 | - |
| Sector ETF (XLB) | 13.5% | 17.8% | 0.56 | 12.8% |
| Equity (SPY) | 16.6% | 12.9% | 0.92 | 25.7% |
| Gold (GLD) | 17.4% | 29.3% | 0.55 | 6.2% |
| Commodities (DBC) | 45.8% | 20.7% | 1.72 | -7.1% |
| Real Estate (VNQ) | 5.7% | 13.5% | 0.16 | 12.7% |
| Bitcoin (BTCUSD) | -34.9% | 43.9% | -0.85 | 16.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SNES | |
|---|---|---|---|---|
| SNES | -81.8% | 119.1% | -0.89 | - |
| Sector ETF (XLB) | 5.8% | 19.1% | 0.20 | 10.1% |
| Equity (SPY) | 12.6% | 17.2% | 0.56 | 12.9% |
| Gold (GLD) | 18.9% | 18.8% | 0.81 | 2.4% |
| Commodities (DBC) | 11.7% | 19.6% | 0.47 | 1.7% |
| Real Estate (VNQ) | 1.0% | 18.8% | -0.05 | 9.1% |
| Bitcoin (BTCUSD) | 10.4% | 52.5% | 0.38 | 11.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SNES | |
|---|---|---|---|---|
| SNES | -80.0% | 149.9% | -0.46 | - |
| Sector ETF (XLB) | 9.7% | 20.7% | 0.41 | 5.3% |
| Equity (SPY) | 15.1% | 18.0% | 0.71 | 6.8% |
| Gold (GLD) | 12.0% | 16.4% | 0.60 | 2.4% |
| Commodities (DBC) | 8.5% | 18.1% | 0.39 | 2.4% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.17 | 5.6% |
| Bitcoin (BTCUSD) | 62.0% | 66.1% | 1.02 | 3.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/8/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | -22.1% | -22.4% | -36.2% |
| 5/12/2026 | 9.0% | -7.8% | 1.8% |
| 3/12/2026 | -15.0% | -23.0% | -31.0% |
| 11/10/2025 | -8.2% | -20.1% | -20.4% |
| 8/7/2025 | -13.0% | -14.5% | -6.9% |
| 5/8/2025 | 8.2% | 8.6% | 11.8% |
| 3/12/2025 | 4.3% | -7.4% | -30.9% |
| 11/12/2024 | -7.1% | -14.9% | 12.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 6 | 5 | 6 |
| # Negative | 17 | 18 | 17 |
| Median Positive | 3.1% | 5.9% | 11.4% |
| Median Negative | -9.6% | -14.7% | -27.2% |
| Max Positive | 9.0% | 8.6% | 14.4% |
| Max Negative | -31.3% | -47.7% | -86.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | -22.1% | -22.4% | -36.2% |
| 5/12/2026 | 9.0% | -7.8% | 1.8% |
| 3/12/2026 | -15.0% | -23.0% | -31.0% |
| 11/10/2025 | -8.2% | -20.1% | -20.4% |
| 8/7/2025 | -13.0% | -14.5% | -6.9% |
| 5/8/2025 | 8.2% | 8.6% | 11.8% |
| 3/12/2025 | 4.3% | -7.4% | -30.9% |
| 11/12/2024 | -7.1% | -14.9% | 12.4% |
| 8/8/2024 | 0.0% | -4.3% | -25.0% |
| 5/9/2024 | -26.2% | -25.8% | -22.8% |
| 2/21/2024 | -19.8% | -20.9% | -34.8% |
| 11/9/2023 | -31.3% | -47.7% | -86.1% |
| 8/10/2023 | 0.0% | 3.1% | -27.2% |
| 5/11/2023 | -9.4% | -7.7% | -11.2% |
| 3/16/2023 | -10.8% | -21.9% | -32.5% |
| 11/14/2022 | -8.5% | -3.4% | -9.2% |
| 8/11/2022 | -12.8% | -21.5% | -37.4% |
| 5/12/2022 | -2.7% | -2.5% | -3.0% |
| 11/10/2021 | 1.9% | -3.2% | -31.6% |
| 8/12/2021 | -0.0% | 8.4% | 11.0% |
| 5/13/2021 | -7.2% | 5.9% | 14.4% |
| 3/25/2021 | -9.6% | -6.6% | -16.8% |
| 11/12/2020 | -1.4% | 2.1% | 2.8% |
| SUMMARY STATS | |||
| # Positive | 6 | 5 | 6 |
| # Negative | 17 | 18 | 17 |
| Median Positive | 3.1% | 5.9% | 11.4% |
| Median Negative | -9.6% | -14.7% | -27.2% |
| Max Positive | 9.0% | 8.6% | 14.4% |
| Max Negative | -31.3% | -47.7% | -86.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/13/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/21/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/17/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/13/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/21/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/17/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 03/29/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/13/2021 | 10-Q |
| 03/31/2021 | 05/14/2021 | 10-Q |
| 12/31/2020 | 03/29/2021 | 10-K |
| 09/30/2020 | 11/13/2020 | 10-Q |
| 06/30/2020 | 08/13/2020 | 10-Q |
| 03/31/2020 | 05/15/2020 | 10-Q |
| 12/31/2019 | 03/17/2020 | 10-K |
| 09/30/2019 | 11/14/2019 | 10-Q |
Insider Activity
Updated 9/15/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Edell, Michael | Chief Executive Officer | Direct | Buy | 9142026 | 0.84 | 1,000 | 840 | 7,560 | Form |
| 2 | Edell, Michael | Chief Executive Officer | Direct | Buy | 9102026 | 0.87 | 2,000 | 1,740 | 6,960 | Form |
| 3 | Edell, Michael | Chief Executive Officer | Direct | Buy | 8172026 | 1.21 | 1,000 | 1,210 | 7,260 | Form |
| 4 | Glenbrook, Capital Management | See footnote | Buy | 8102026 | 1.30 | 6,490 | 8,422 | 1,400,600 | Form | |
| 5 | Glenbrook, Capital Management | See footnote | Buy | 8102026 | 1.30 | 15,000 | 19,443 | 1,390,569 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Edell, Michael | Chief Executive Officer | Direct | Buy | 9142026 | 0.84 | 1,000 | 840 | 7,560 | Form |
| 2 | Edell, Michael | Chief Executive Officer | Direct | Buy | 9102026 | 0.87 | 2,000 | 1,740 | 6,960 | Form |
| 3 | Edell, Michael | Chief Executive Officer | Direct | Buy | 8172026 | 1.21 | 1,000 | 1,210 | 7,260 | Form |
| 4 | Glenbrook, Capital Management | See footnote | Buy | 8102026 | 1.30 | 6,490 | 8,422 | 1,400,600 | Form | |
| 5 | Glenbrook, Capital Management | See footnote | Buy | 8102026 | 1.30 | 15,000 | 19,443 | 1,390,569 | Form | |
| 6 | Glenbrook, Capital Management | See footnote | Buy | 7222026 | 1.47 | 35,000 | 51,569 | 1,558,598 | Form | |
| 7 | Edell, Michael | Chief Executive Officer | Direct | Buy | 7072026 | 1.43 | 1,000 | 1,430 | 7,150 | Form |
| 8 | Glenbrook, Capital Management | See footnote | Buy | 7022026 | 1.51 | 35,000 | 52,731 | 1,540,987 | Form | |
| 9 | Glenbrook, Capital Management | See footnote | Buy | 6292026 | 1.52 | 5,172 | 7,884 | 1,505,839 | Form | |
| 10 | Glenbrook, Capital Management | See footnote | Buy | 6292026 | 1.56 | 6,812 | 10,598 | 1,528,810 | Form | |
| 11 | Glenbrook, Capital Management | See footnote | Buy | 6292026 | 1.53 | 9,442 | 14,435 | 1,491,864 | Form | |
| 12 | Glenbrook, Capital Management | See footnote | Buy | 6292026 | 1.55 | 3,990 | 6,185 | 1,498,014 | Form | |
| 13 | Glenbrook, Capital Management | See footnote | Buy | 6222026 | 1.66 | 5,000 | 8,296 | 1,596,731 | Form | |
| 14 | Glenbrook, Capital Management | See footnote | Buy | 6222026 | 1.61 | 3,264 | 5,268 | 1,545,161 | Form | |
| 15 | Edell, Michael | Chief Executive Officer | Direct | Buy | 6092026 | 1.55 | 1,000 | 1,550 | 6,200 | Form |
| 16 | Glenbrook, Capital Management | See footnote | Buy | 6082026 | 1.61 | 7,000 | 11,304 | 1,540,752 | Form | |
| 17 | Glenbrook, Capital Management | See footnote | Buy | 6082026 | 1.57 | 13,159 | 20,685 | 1,488,816 | Form | |
| 18 | Glenbrook, Capital Management | See footnote | Buy | 6082026 | 1.65 | 8,230 | 13,547 | 1,537,433 | Form | |
| 19 | Glenbrook, Capital Management | See footnote | Buy | 5182026 | 1.59 | 10,000 | 15,878 | 1,469,914 | Form | |
| 20 | Edell, Michael | Chief Executive Officer | Direct | Buy | 5182026 | 1.61 | 1,000 | 1,615 | 4,845 | Form |
| 21 | Glenbrook, Capital Management | See footnote | Buy | 5182026 | 1.65 | 7,120 | 11,747 | 1,510,813 | Form | |
| 22 | Edell, Michael | Chief Executive Officer | Direct | Buy | 5182026 | 1.70 | 2,000 | 3,398 | 3,398 | Form |
| 23 | Glenbrook, Capital Management | See footnote | Buy | 5182026 | 1.72 | 15,000 | 25,862 | 1,566,578 | Form | |
| 24 | Glenbrook, Capital Management | See footnote | Buy | 4302026 | 1.47 | 3,000 | 4,407 | 1,312,750 | Form | |
| 25 | Glenbrook, Capital Management | See footnote | Buy | 3172026 | 1.79 | 19,725 | 35,355 | 1,596,374 | Form | |
| 26 | Glenbrook, Capital Management | See footnote | Buy | 3172026 | 1.86 | 5,060 | 9,392 | 1,616,583 | Form | |
| 27 | Glenbrook, Capital Management | See footnote | Buy | 3172026 | 1.95 | 146,249 | 285,434 | 1,689,879 | Form | |
| 28 | Glenbrook, Capital Management | See footnote | Buy | 2192026 | 2.40 | 34,613 | 83,140 | 1,691,515 | Form | |
| 29 | Glenbrook, Capital Management | See footnote | Buy | 2192026 | 2.29 | 10,481 | 24,001 | 1,533,379 | Form | |
| 30 | Glenbrook, Capital Management | See footnote | Buy | 2192026 | 2.29 | 40,807 | 93,493 | 1,510,103 | Form | |
| 31 | Glenbrook, Capital Management | See footnote | Buy | 2132026 | 1.89 | 15,390 | 29,106 | 1,198,453 | Form | |
| 32 | Glenbrook, Capital Management | See footnote | Buy | 2132026 | 1.72 | 7,956 | 13,688 | 1,063,802 | Form | |
| 33 | Glenbrook, Capital Management | See footnote | Buy | 2132026 | 1.73 | 8,000 | 13,874 | 1,058,476 | Form | |
| 34 | Glenbrook, Capital Management | See footnote | Buy | 2062026 | 1.77 | 2,884 | 5,106 | 1,066,468 | Form | |
| 35 | Glenbrook, Capital Management | See footnote | Buy | 2062026 | 1.82 | 5,685 | 10,373 | 1,093,853 | Form | |
| 36 | Glenbrook, Capital Management | See footnote | Buy | 2032026 | 1.98 | 42,739 | 84,418 | 1,172,844 | Form | |
| 37 | Glenbrook, Capital Management | See footnote | Buy | 2032026 | 1.87 | 5,399 | 10,106 | 1,031,448 | Form | |
| 38 | Leach, Jacob Steven | Direct | Sell | 11182025 | 2.71 | 62 | Form | |||
| 39 | Szot, Matthew K | Direct | Sell | 11172025 | 2.75 | 1 | Form |
Industry Resources
| Materials Resources |
| Chemical & Engineering News (C&EN) |
| Mining.com |
| Plastics News |
| Specialty Chemicals Resources |
| SpecialChem |
| Chemical Week |
| ICIS |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.